Résumé
Random systematic biopsy is the standard method for diagnosing prostate cancer. As the improvement of multi-parameter magnetic resonance imaging (mpMRI) and its corresponding scoring system, magnetic resonance imaging(MRI)-targeted target biopsy has been an effective alternative to traditional systemic puncture. Prostate imaging reporting and data system(PI-RADS) is the most commonly used MRI-scoring system. The negative rate of prostate cancer in the patient with PI-RADS scores of 1 and 2 was 90.8%(95% CI, 88.1%~93.1%), and the diagnosis rates of clinically meaningful prostate cancer in the patient with PI-RADS scores of 3, 4, and 5 was 20.9%, 58.3% and 80.7%, respectively. That means that MRI targeted prostate biopsy can more effectively detect clinically meaningful prostate cancer on the basis of reducing unnecessary punctures. There are three effective MRI guided target biopsy method for prostate biopsy, including MRI guided target biopsy(MRI-TB), MRI-TRUS fusion target biopsy(FUS-TB) and cognitive fusion target biopsy(COG-TB). Considering the false negative rate and discrepant image quality, MRI-targeted target biopsy still cannot completely replace the traditional systemic puncture. However, it can be seen that the targeted combined system puncture is the future development trend.